Market research
ONCY Oncolytics Biotech Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 65M
- P/E ratio
- Not available
- Analyst target
- 4.1796
- Dividend yield
- Not available
- Beta
- 1.16
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 65M
- P/E ratio
- Not available
- Analyst target
- 4.1796
- Dividend yield
- Not available
- Beta
- 1.16
About
About Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal ("GI") tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Research context
Oncolytics Biotech Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ONCY discussion.
5 years, 6 months ago
Oncolytics Biotech Inc is currently in a long term downtrend where the price is trading 4.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Oncolytics Biotech Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 51.9% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 21.0% to $-6M since the same quarter in the previous year.
Based on the above factors, Oncolytics Biotech Inc gets an overall score of 3/5.